会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Derivatives of bicyclic lactols
    • 双环乳糖的衍生物
    • US4257962A
    • 1981-03-24
    • US942819
    • 1978-09-15
    • Tibor SzaboLaszlo InstitorisGabor KovacsGyula DalmadiBela KoszegiIstvan Stadler
    • Tibor SzaboLaszlo InstitorisGabor KovacsGyula DalmadiBela KoszegiIstvan Stadler
    • C07C405/00A61K31/34A61K31/343A61P7/02A61P25/02A61P35/00C07D307/935
    • C07D307/935
    • Racemic or optically active compounds with antitumor activity of the formula: ##STR1## wherein X is oxygen or sulfur;R.sup.1 is hydrogen, C.sub.1 to C.sub.4 alkanoyl, benzoyl or phenyl-substituted benzoyl;R.sup.2 is hydrogen or C.sub.1 to C.sub.4 alkanoyl;R.sup.3 is C.sub.2 to C.sub.40 straight or branched chain alkyl substituted by hydroxy, epoxy, amino, C.sub.1 to C.sub.6 alkylamino, C.sub.1 to C.sub.6 dialkylamino, C.sub.1 to C.sub.6 alkanoyloxy or, C.sub.1 to C.sub.4 alkoxycarbonyl; cyclohexyl, phenyl unsubstituted or substituted by halogen, amino, C.sub.1 to C.sub.4 alkyl-substituted amino, C.sub.1 to C.sub.4 alkoxy, nitro, or hydroxy; C.sub.1 to C.sub.6 alkanoyl; allyl or phenyl-C.sub.1 to C.sub.4 alkyl unsubstituted or substituted by a C.sub.2 to C.sub.6 alkene group; or where X is sulfur R.sup.3 is as defined above or is C.sub.1 to C.sub.40 straight or branched chain alkyl; and.about. represents the exo- or endo-steric position in the ring and indicates an .alpha.- or .beta.-steric position in the side chain are disclosed.
    • 具有下式的抗肿瘤活性的外消旋或光学活性化合物:其中X是氧或硫; R1是氢,C1至C4烷酰基,苯甲酰基或苯基取代的苯甲酰基; R2是氢或C1-C4烷酰基; R3为C2至C40被羟基,环氧基,氨基,C1至C6烷基氨基,C1至C6二烷基氨基,C1至C6烷酰氧基或C1至C4烷氧基羰基取代的直链或支链烷基; 环己基,未取代或被卤素取代的苯基,氨基,C1至C4烷基取代的氨基,C1至C4烷氧基,硝基或羟基; C1至C6烷酰基; 烯丙基或未被取代或被C2至C6烯基取代的苯基-C1至C4烷基; 或其中X为硫的R 3如上所定义或为C 1至C 40直链或支链烷基; 而DIFFERENCE表示环中的外 - 或内 - 立体位置,并且表示侧链中的α或β-甾族位置。
    • 6. 发明授权
    • Contraceptive vaginal tablets
    • 避孕阴道片
    • US4565694A
    • 1986-01-21
    • US621905
    • 1984-06-07
    • Andras KovacsRudolf SzebeniBela Koszegi
    • Andras KovacsRudolf SzebeniBela Koszegi
    • A61K31/12A61K9/00A61K9/02A61K31/122A61K31/19A61K31/715A61K31/79A61K33/00A61K47/32A61K47/38
    • A61K9/0034Y10S514/843
    • The invention relates to contraceptive vaginal tablets as well as to a process for preparing them. The tablets of the invention have the following composition:0.2 to 3 parts by weight of boric acid,10 to 20 parts by weight of tartaric acid,1 to 2 parts by weight of vitamin K.sub.3 -sodium bisulfite adduct,0.8 to 1.2 parts by weight of polyvinyl pyrrolidone,2 to 5 parts by weight of magnesium stearate,8 to 12 parts by weight of carboxymethyl cellulose,8 to 12 parts by weight of lactose and50 to 65 parts by weight of microcrystalline cellulose.The vaginal tablets contain preferably 5 to 10 mg of vitamin K.sub.3 -sodium bisulfite adduct and have a total weight of 500 mg.The tablets of the invention are prepared preferably in such way that the boric acid, the tartaric acid and the vitamin K.sub.3 -sodium bisulfite adduct, as well as the polyvinyl pyrrolidone, the magnesium stearate, the carboxymethyl cellulose, the lactose and the microcrystalline cellulose are homogenized separately to powder mixtures thereafter the powder mixtures are mixed and pressed to tablets.The tablets should be wetted and put into the back-vaginal fornix 10 minutes before the coitus.
    • PCT No.PCT / HU83 / 00052 Sec。 371日期1984年6月7日 102(e)日期1984年6月7日PCT提交1983年10月7日PCT公布。 公开号WO84 / 01502 日期1984年4月26日。本发明涉及避孕阴道片及其制备方法。 本发明的片剂具有以下组成:0.2〜3重量份的硼酸,10〜20重量份的酒石酸,1〜2重量份的维生素K 3 - 亚硫酸氢钠加合物,0.8〜1.2重量份 的聚乙烯吡咯烷酮,2〜5重量份的硬脂酸镁,8〜12重量份的羧甲基纤维素,8〜12重量份的乳糖和50〜65重量份的微晶纤维素。 阴道片剂优选含有5〜10mg维生素K 3 - 亚硫酸氢钠加合物,总重量为500mg。 本发明的片剂优选以硼酸,酒石酸和维生素K 3 - 亚硫酸氢钠加合物以及聚乙烯吡咯烷酮,硬脂酸镁,羧甲基纤维素,乳糖和微晶纤维素等的方式制备 与粉末混合物分别均化,然后将粉末混合物混合并压制成片剂。 应将片剂浸湿,并在肛门前10分钟放入背阴道穹窿。